A personalized selection of choline precursors in evidence

Close metadata

Recommended articles:

Asthenic disorders correction with Recognan. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):57-62

Cognitive impairment in patients with arterial hypertension. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):41-48

Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):92-99

Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):43-47

Pharmacological effects of fonturacetam (Actitropil) and prospects for its clinical use. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):21-31

Recognan (citicoline) prescribing in cerebrovascular diseases and type 2 diabetes mellitus patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):23-27

Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):7-18

Modern aspects of chronic cerebral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113

Possibilities of physiotherapy in glaucomatous optic neuropathy after glaucoma surgery. Russian Annals of Ophthalmology. 2024;(3):88-94

Neuroprotective therapy for age-related macular degeneration. Russian Annals of Ophthalmology. 2024;(6):152-158

The analysis of mechanisms of the neuroprotective effect of choline precursors reveals the primary effects of citicoline on the processes of repair of neuronal membranes, a decrease in the degeneration of free fatty acids, and choline alfoscerate, an increase in the production of the neurotransmitter acetylcholine. Although citicoline has a lesser effect on choline secretion than choline alfoscerate, the combination of choline and cytidine in its composition is a universal tool to reduce symptoms of cerebral ischemia, to stabilize cognitive status, superior to the standard benefits of choline. Various mechanisms of the action of citicoline enable to recommend it as a drug effective both in the acute phase of the disease and in the delayed period, giving it the status of a universal nootropic compound.

Keywords:

neuroprotection

citicoline

choline alfoscerate

Authors:

Putilina M.V.

Pirogov Russian National Research Medical University

ORCID: 0000-0002-8655-8501

Received:

23.04.2020

Accepted:

27.04.2020

List of references:

Raymond Chuen-Chung Chang and Yuen-Shan Ho Introductory Chapter: Concept of Neuroprotection — A New Perspective Submitted: January 11th 2019. Reviewed: March 4th 2019. Published: March 27th 2019. https://doi.org/10.5772/intechopen.85631.
Putilina MV. Eatures of combination neuroprotective therapy of acute disorders of cerebral circulation of breast cancer. Russian Medical Journal. 2009;4:261-267. (In Russ.).
Piradov MA, Tanashyan MM, Domashenko MA, Sergeev DV, Maksimova MYu. Neuroprotection in cerebrovascular diseases: the search for life on Mars or future direction of treatment? Part 1. Acute disorders of cerebral circulation. Annals of Clinical and Experimental Neurology. 2015;9(1):41-50. (In Russ.).
Secades JJ, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, Oudovenko N. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cerebrovasc Dis. 2016;25(8):1984-1996. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.04.010
Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016;63(03):1-73.
Secades JJ, Alvarez-Sabín J, Castillo J. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Rand omized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cerebrovasc Dis. 2016;25(8):1984-1996. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.04.010
Lee BK, Jung YS. Sustained Intracellular Acidosis Triggers the Na+/H+ Exchager-1 Activation in Glutamate Excitotoxicity. Biomol Ther (Seoul). 2017. https://doi.org/10.4062/biomolther.2017.018
Topuzova MP, Alekseeva TM, Vavilova TV, Sirotkina OV, Klocheva EG. Circulating endothelial cells and their precursors as a marker of endothelial dysfunction in patients with arterial hypertension who have suffered an ischemic stroke (review). Arterial Hypertension. 2018;24(1):57-64. (In Russ.). https://doi.org/10.18705/1607-419X-2018-24-1-57-64
Yuliani S, Widyarini S, Mustofa, Partadiredja G Turmeric extract inhibits apoptosis of hippocampal neurons of trimethyltin-exposed rats. Bratisl Lek Listy. 2017;118(3):142-148. https://doi.org/10.4149/bll_2017_028
Marston KJ, Brown BM, Rainey- Smith SR, Peiffer JJ. Resistance exercise- induced responses in physiological factors linked with cognitive health. Journal of Alzheimer’s Disease. 2019. https://doi.org/10.3233/JAD-181079
Ye J, Lin H, Mu J, Cui X, Ying H, Lin M, Wu L, Weng J, Lin X. Effect of basic fibroblast growth factor on hippocampal cholinergic neurons in a rodent model of ischaemic encephalopathy. Basic Clin Pharmacol Toxicol. 2010;107(6):931-939. https://doi.org/10.1111/j.1742-7843.2010.00603.x
Putilina MV, Teplova NV. Algorithms of rational therapy in chronic brain ischemia. Clinical recommendations. Nervous Diseases. 2019;1:11-16. (In Russ.). https://doi.org/10.24411/2226-0757-2019-12074
Chang RCC, Chiu K, Ho YS, So KF. Modulation of neuroimmune responses on glia in the central nervous system: Implication in therapeutic intervention against neuroinflammation. Cellular & Molecular Immunology. 2009;6:317-326.
Adibhatla RM, Hatcher JF, Larsen EC. CDP-choline significantly restores phosphatidylcholine levels by differentially affecting Phospholipase A2 and CTP:phosphocholine cytidylyltransferase after Stroke. J Biol Chem. 2006;281:10:6718-6725.
Tavoosi N, Davis-Harrison R, Pogorelov T, Ohkubo Y, Arcario M, Rienstra Ch, Morrissey J. Molecular Determinants of Phospholipid Synergy in Blood Clotting. J Biol Chem. 286:23247‐23253. https://doi.org/10.1074/jbc.M111.251769
Kovalenko T, Panteleev M, Sveshnikova A. Substrate delivery mechanism and the role of membrane curvature in factor X activation by extrinsic tenase. Journal of Theoretical Biology. 2017;435:125-133. PMID: 28935233. https://doi.org/10.1016/j.jtbi.2017.09.015
Citicoline. Register of medicines of the Russian Federation. https://www.rlsnet.ru
Martí‐Carvajal A, Valli C, Solà I, Martí‐Fàbregas J, Bonfill Cosp X. Citicoline for treating people with acute ischemic stroke. Cochrane Systematic Review — Intervention — Protocol Version published: 02 July 2018. https://doi.org/10.1002/14651858.cd013066
Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, Schwiderski U, Gammans R. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol. 2000;48(5):713-722. PMID: 11079534.
Secades JJ, Alvarez-Sabin J. Citicoline in intracerebral haemorrhage, a double blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis. 2006;21(5-6):380-385. https://doi.org/10.1159/000091547
Chua RH. Role of intravenous citcoline for supratentorial hemorrhage. Cerebrovasc Dis. 2007;23(suppl 2):73.
Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;2:18. https://doi.org/10.1002/14651858.CD000269
Silveri MM, Dikan J, Ross AJ, Jensen JE, Kamiya T, Kawada Y, Renshaw PF, Yurgelun-Todd DA. Citicoline enhances frontal lobebioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. 2008;21(10):1066-1075. PMID: 18816480. https://doi.org/10.1002/nbm.1281
Gozes I. Neuroprotection in Alzheimer’s Disease Imprint: Academic PressPublished Date: 17th January 2017 P.: 342 Hardcover ISBN: 9780128036907. eBook ISBN: 9780128037126
Karpov SM, Gnezditsky VV, Frantseva VO, Vlasova DYu, Kaloev AD. the Use of cerakson in the treatment of cognitive disorders in patients with dyscirculatory encephalopathy. Kuban Medvestnik. 2012;12:52-56. (In Russ.).
Vakhnina NV, Zakharov VV. Disturbances of gait and postural stability in chronic cerebral ischemia. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(1):78-84. (In Russ.). https://doi.org/10.17116/jnevro20171171178-84
Putilina MV, Shabalina NI. Possibilities of early correction of mild and moderate cognitive disorders in patients with dyscirculatory encephalopathy. Attending Physician. 2010;9:100-103. (In Russ.).
Zmergrad MV. Vertigo with a diagnosis of dyscirculatory encephalopathy. Medical Advice. 2014;5:22-26. (In Russ.).
Putilina MV. Ischemic cochleovestibular syndromes. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2012;112(6):35-39. (In Russ.).
Mashin VV, Belova LA, Bakhtogarimov IR, Bergel’son TM, Sharafutdinova RR. Multicenter observational program for evaluating the effectiveness of the drug rekogan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(8):39-43. (In Russ.). https://doi.org/10.17116/jnevro20171178139-43
Petrova D, Maslarov D, Angelov I, Zekin D. Analysis of therapeutic efficacy of citicoline in patients with vertigo of central origin and vascular aetiology. Am J Neuroprotec Neuroregen. 2012;4:1:1-8. https://doi.org/10.1166/ajnn.2012.1043
Chutko LS, Surushkina SYu, Yakovenko EA, Anisimova TI, Karpovskaya EB, Vasilenko VV, Didur MD, Volov MB. Impairments of cognitive control in patients with somatoform disorders and their treatment. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2019;4:27-32. (In Russ.). https://doi.org/10.17116/jnevro201911904132
Nemkova SA, Semenov DV, Petrova EA, Savchenko DV, Zavadenko NN, Vozvyshaeva MYu, Kanishcheva AS, Ralleva, Loginova EM, Tsvetkov DA, Charikova EV, Romanenko NI, Zagar’yan DA, Boldyrev VG. Cognitive and emotional disorders in university students and teachers: the possibility of treatment with recognan (citicoline). Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;12:11-18. (In Russ.). https://doi.org/10.17116/jnevro201811812111
McGlade E. Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women. https://doi.org/10.4236/fns.2012.36103
Bruce S.E, Werner K.B, Preston B.F, Baker L.M. Improvements in concentration, working memory and sustained attention following consumption of a natural citicoline-caffeine beverage. Int J Food Sci Nutr. 2014;65:1003-1007. https://doi.org/10.3109/09637486.2014.940286
Choline alfoscerate. Register of medicines of the Russian Federation. https://www.rlsnet.ru
Burchinsky SK. Complex correction of anxiety and cognitive disorders in angioneurology: goals, tasks, tools. International Journal of Neurology. 2017;8(94):73-76. (In Russ.). https://doi.org/10.22141/2224-0713.8.94.2017.120704
Odinak MM, Voznyuk IA, Piradov MA, Rumyantseva SA, Kuznetsov AN, Yanishevsky SN. Multicenter (pilot) study of the effectiveness of Gliatilin in acute ischemic stroke. Annals of Clinical and Experimental Neurology. 2010;4(1):20-29. (In Russ.).
Parnetti L, Mignini F, Tomassoni D. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approach or need for re-evaluation? J Neurol Sci. 2007;257:264-269. https://doi.org/10.1016/j.jns.2007.01.043
Colucci L, Bosco M, Ziello AR, Rea R, Amenta F. Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review. J Exp Pharmacol. 2012;4:163-172. Published online 2012 Dec 11. https://doi.org/10.2147/JEP.S35326
Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP‐choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;2. https://doi.org/10.1002/14651858.CD000269.pub3
Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev. 2001;122(16):2041-2055. PMID: 11589921. https://doi.org/10.1016/s0047-6374(01)00312-8
Dzyak L, Tsurkalenko ES. The role of cholinergic deficiency in the pathogenesis of neuropsychiatric diseases. International Neurological Journal. 2019;3(105):33-45. (In Russ.). https://doi.org/10.22141/2224-0713.3.105.2019.169917
Amenta F, Carotenuto A, Fasanaro AM, Lanari A, Previdi P, Rea R. Analisi comparativa della sicurezza/efficacia degli inibitori delle colinesterasi e del precursore colinergico colina alfoscerato nelle demenze ad esordio nell’eta adulta. G. Gerontol. 2010;58:64-68.
De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25:1:178-193.
Amenta F, et al. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer’s disease with cerebrovascular injury: interim results. J Neurol Sci. 2012;322(1-2):96-101. https://doi.org/10.1016/j.jns.2012.07.003
Acosta J, Nombela M, Palao A, Pastor M, Recuero J. Multicentre trial: treatment of Parkinson’s disease with CDP-choline (citicholine). In Bartko D, Turcani P, Stern G. New trends in clinical neuropharmacology: calcium antagonists, acute neurology, headache and movement disorders. London: John Libbey; 1988.
Putilina MV. Aging as a degenerative process. Safe strategies for dementia treatment in elderly patients. Consilium Medicum. 2018;20(2):24-29. (In Russ.). https://doi.org/10.26442/2075-1753_2018.2.24-29
Recognan. National register of medicines of the Russian Federation. https://www.grls.rosminzdrav.ru
Grupke S, Hall J, Dobbs M, Bix G, Fraser J. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: From review to preview. Clinical Neurology and Neurosurgery. 2015;129:1-9. Epub 2014 Dec 3. https://doi.org/10.1016/j.clineuro.2014.11.013
Tayebati SK, Martinelli I, Moruzzi M, Amenta F, Tomassoni D. Choline and Choline alphoscerate Do Not Modulate Inflammatory Processes in the Rat Brain. Nutrients. 2017;9(10):1084. PMID: 28961195; PMCID: PMC5691701. https://doi.org/10.3390/nu9101084

Close metadata